ATE214161T1 - Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse - Google Patents

Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse

Info

Publication number
ATE214161T1
ATE214161T1 AT99929407T AT99929407T ATE214161T1 AT E214161 T1 ATE214161 T1 AT E214161T1 AT 99929407 T AT99929407 T AT 99929407T AT 99929407 T AT99929407 T AT 99929407T AT E214161 T1 ATE214161 T1 AT E214161T1
Authority
AT
Austria
Prior art keywords
cleaved
psa
free psa
diagnosing
free
Prior art date
Application number
AT99929407T
Other languages
English (en)
Inventor
Jean-Philippe Charrier
Carole Tournel
Michel Jolivet
Original Assignee
Bio Merieux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Merieux filed Critical Bio Merieux
Application granted granted Critical
Publication of ATE214161T1 publication Critical patent/ATE214161T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99929407T 1998-07-03 1999-07-05 Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse ATE214161T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9808702A FR2780791B1 (fr) 1998-07-03 1998-07-03 Methode de depistage ou de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate et procede de mise en oeuvre
PCT/FR1999/001622 WO2000002052A1 (fr) 1998-07-03 1999-07-05 Methode de diagnostic d'un adenocarcinome ou d'une pathologie benigne de la prostate

Publications (1)

Publication Number Publication Date
ATE214161T1 true ATE214161T1 (de) 2002-03-15

Family

ID=9528375

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99929407T ATE214161T1 (de) 1998-07-03 1999-07-05 Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse

Country Status (9)

Country Link
US (1) US6929918B1 (de)
EP (1) EP1095276B1 (de)
JP (1) JP4364437B2 (de)
AT (1) ATE214161T1 (de)
AU (1) AU4623599A (de)
CA (1) CA2336174C (de)
DE (1) DE69900998T2 (de)
FR (1) FR2780791B1 (de)
WO (1) WO2000002052A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2807438B1 (fr) * 2000-04-10 2004-09-17 Bio Merieux Nouveaux anticorps reconnaissant specifiquement le psa libre inactif, et leurs applications
ATE335765T1 (de) * 2000-05-24 2006-09-15 Hoffmann La Roche Antikörper gegen spezielle formen des propsa und deren verwendung in immunoassays
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
EP1317511B1 (de) 2000-09-06 2005-01-19 Evotec OAI AG Oxazinderivate
JP4681175B2 (ja) * 2001-09-28 2011-05-11 三菱化学メディエンス株式会社 播種性血管内凝固症候群及びその発症前段階を検出する方法
GB0217831D0 (en) * 2002-08-01 2002-09-11 Sweetapple Matthew J Risqué method and device
US20070254317A1 (en) * 2004-03-03 2007-11-01 Biomerieux Method for Detecting the Activatable Free Form of Psa and the Use Thereof for Diagnosing Benign Pathologies of the Prostate and Adenocarcinoma of the Prostate
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
CN102520161A (zh) * 2012-01-05 2012-06-27 中南大学 一种用于spr双通道法检测前列腺特异性抗原的生物传感芯片、试剂盒，检测方法
TWI638277B (zh) 2012-03-05 2018-10-11 Ｏｐｋｏ診斷法有限責任公司 用於確定前列腺癌相關事件之機率之分析系統及方法
US9575053B2 (en) * 2012-03-30 2017-02-21 Kyoto University Urinary biomarker for use in test for prostate cancer
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma

Also Published As

Publication number Publication date
US6929918B1 (en) 2005-08-16
JP4364437B2 (ja) 2009-11-18
AU4623599A (en) 2000-01-24
FR2780791A1 (fr) 2000-01-07
EP1095276A1 (de) 2001-05-02
CA2336174A1 (fr) 2000-01-13
WO2000002052A1 (fr) 2000-01-13
EP1095276B1 (de) 2002-03-06
DE69900998D1 (de) 2002-04-11
CA2336174C (fr) 2012-05-15
JP2002519701A (ja) 2002-07-02
FR2780791B1 (fr) 2000-09-01
DE69900998T2 (de) 2002-11-07

Similar Documents

Publication Publication Date Title
DE69623264D1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
ATE214161T1 (de) Verfahren zur diagnose adenokarzinom oder benigne pathologie der vorsteherdrüse
Oesterling Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
DE69519796T2 (de) PTPalpha-Bestimmung in der Tumordiagnose und -Prognose
EP1099102A4 (de) Spurendetektion von analyten mit hilfe artifizieller olfaktometrie
DE69937368D1 (de) Nachweis von erkrankungen der nieren und behandlung
HUP9701717A2 (hu) Eljárás cPSA-meghatározására
Wajsman et al. Clinical significance of serum alkaline phosphatase isoenzyme levels in advanced prostatic carcinoma
Jackson Jr et al. Prostate specific antigen regression and progression after androgen deprivation for localized and metastatic prostate cancer
ATE350662T1 (de) Markerproteine für prostatakrebs
Tavassoli et al. Elevation of serum acid phosphatase in cancers with bone metastasis
Larsen et al. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease
DE69704031D1 (de) Test zur diagnose eines erhöhten brustkrebs-risikos
ATE126599T1 (de) Verfahren zur bestimmung von anti-rns- antikörpern.
Green et al. Thickness is not an accurate gauge of prognosis of primary cutaneous melanoma
FR2810114B1 (fr) Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
ATE130100T1 (de) Verfahren zur immunologischen erkennung maligner tumore und kit zur durchführung dieses verfahrens.
ATE135468T1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
FI943355A0 (fi) Menetelmä tietyn syövän esiintymismahdollisuuden arvioimiseksi potilaassa
WO1998046993A3 (en) Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor
ATE283479T1 (de) Verfahren und testsatz zur bestimmung der analytkonzentration im blut
Dutkiewicz et al. Effect of digital rectal examination on plasma prostate-specific antigen (PSA)
ATE485515T1 (de) Verfahren zur diagnose einer person mit multipler sklerose
Schellhammer et al. Bone marrow acid phosphatase by counterimmune electrophoresis: pre-treatment and post-treatment correlations
Speights Jr et al. Assessment of serum gamma glutamyl transpeptidase levels in low stage renal cell carcinoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties